Assessing the Economic Burden of Under Diagnosed Dry Eye Disease

EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments

EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease

EP: 3.Navigating Different Subtypes of Dry Eye Disease

EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes

EP: 5.Updating Formularies: Considerations for Dry Eye Disease

Now Viewing

EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease

EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease

EP: 8.Resource Allocation in the Treatment of Dry Eye Disease

EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease

EP: 10.Annual Health Care Costs of Managing Dry Eye Disease

EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease

EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease

EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease

EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Kabiri estimates over 35 million Americans have undiagnosed or untreated dry eye disease (DED). With growing prevalence from aging demographics and digital device use, costs of uncontrolled DED will likely mushroom. Only a small subset of identified DED patients receive prescription therapy, representing huge unmet need.

Parekh notes the uncontrolled impact of DED on visual function and economic burden is comparable to retinal disease and glaucoma. Even after otherwise successful cataract surgery, residual DED impairs outcomes. Growing prevalence with prolonged device use raises the societal impact of DED. Comprehensive payer coverage and peer education around the rising prominence of DED will be key.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.